Cramer Says It's Time To Buy The Dip on JNJ

On Tuesday morning's Squawk on the Street, Jim Cramer told viewers to step in on a mid-session drop in Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction).

24/7 Wall Street • 20 hours ago

Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026

First presentation of pivotal Phase 3 CAPLYTA ® data in adults with bipolar mania underscores the asset's potential across mood disorders New SPRAVATO ® analyses and schizophrenia research emphasize a focus on complex, high-burden neuropsychiatric conditions TITUSVILLE, N.J., Sept. 8, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026 Psych Congress Annual Meeting (September 15-19, New Orleans, LA).

PRNewsWire • a day ago

Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Johnson & Johnson (JNJ) reached $269.12 at the closing of the latest trading day, reflecting a -2.22% change compared to its last close.

Zacks Investment Research • 12 hours ago

JEPI Is an Income Machine—But These 3 Dividend Stocks Don't Cap Your Upside

JEPI's monthly paycheck looks irresistible until you see exactly what the fund surrenders to produce it. Three Dividend Kings quietly sidestep that tradeoff, and the difference compounds in ways most income investors never stop to calculate.

24/7 Wall Street • a day ago

Want Dividends to Pay Your Medicare Premiums? Here's How Much You Need

Medicare Part B premiums keep climbing, and Social Security checks keep shrinking to cover them. Three Dividend Kings with very different yields and coverage profiles could shift that math entirely in a retiree's favor.

24/7 Wall Street • a day ago

Dividend Growth Vs. High Yield - The Winner Is Clear

Two Paths to Compounding: DGR (Dividend Growth Rate) compounds primarily through per-share dividend growth and multiple expansion, while high-yield strategies compound through rapid share count accumulation when distributions are reinvested. The PTY vs. JNJ Test (2003–2026): Does the aristocrat catch up to the high yielder? The Fallen Angel Test (VFC vs. MPW): When things go wrong, is it better to have a fallen aristocrat or a high yielder?

Seeking Alpha • a day ago

Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble?

Three defensive blue chips entered 2026 promising safety, but their returns split into wildly different tiers, and the reason one name lapped the others exposes a fault line in how investors define defensive in the first place.

24/7 Wall Street • Sep 7, 2026

Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?

Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.

Zacks Investment Research • Sep 7, 2026

3 Dividend Kings Built to Keep Raising Your Income When Rates Rise

Treasury yields near a one-year high are punishing most dividend stocks, but a handful of Dividend Kings kept signing bigger checks every single quarter without missing a beat. The question is whether their balance sheets can keep that streak alive.

24/7 Wall Street • Sep 5, 2026

Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect.

Sixty-four straight years of dividend growth sounds like a headline, but the real story is what keeps that streak alive even as one of JNJ's biggest drugs faces a brutal competitive hit.

24/7 Wall Street • Sep 4, 2026